Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Multi-Drug Resistance, Cancer Stem Cell Research, and ADME/Tox Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ABCG2 (Breast Cancer Resistance Protein) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ABCG2 Full-Length Membrane Protein / Overexpressing Cell Extract Sequence Verified. Optimal for membrane-bound assays and native conformation. |
View ABCG2 Products |
| Gene Delivery | ABCG2 Promise-ORF / Lentivirus Premade Particles Full-length ORF with Puromycin selection. Codon-optimized for mammalian expression. |
View ABCG2 Products |
| Mutant Library | ABCG2 R482G/T Mutant Lentivirus Gain-of-function variants for substrate specificity studies. Sequence Verified. |
View ABCG2 Products |
| Benchmark Ab | Anti-ABCG2/CD338 (5D3 Sequence) Recombinant positive control for flow cytometry and conformational binding studies. |
View ABCG2 Products |
| Validator | ABCG2 siRNA Set For knockdown verification and specificity control in drug efflux assays. |
View ABCG2 Products |
| Cross-Reactivity Panel | Anti-ABCB1 (MDR1) Antibody Positive control for selectivity screening vs P-glycoprotein. |
View ABCB1 Products |
| Related Target A | ABCB1 (MDR1/P-glycoprotein) Parallel efflux pathway; critical for cross-transporter selectivity assays and combination MDR studies. |
View ABCB1 Products |
| Related Target B | ABCC1 (MRP1) Glutathione-conjugate transporter; compensatory resistance mechanism. |
View ABCC1 Products |
| Related Target C | TOP1 (Topoisomerase I) Direct target of ABCG2 substrate drugs (SN-38, topotecan) for combination rationale and payload optimization. |
View TOP1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Topology & Native Conformation Maintenance | Lentivirus-based stable cell lines in HEK293 preserve native membrane insertion, glycosylation, and homodimerization. Endotoxin <1EU/ug. Sequence Verified. |
| Efflux Assay Standardization | Strictly Sequence Verified full-length clones ensuring consistent ATPase and transporter kinetics. Full-length membrane protein in native lipid environment. |
| Lack of Controls & Off-target Specificity | Validated siRNA included for gene-specific knockdown. Clinical Benchmark Antibodies for FACS. ABCC1 and ABCB1 reference reagents for parallel counter-screening. |
| Cross-species Preclinical Translation (Human vs Mouse) | Human and Mouse ABCG2 Ortholog Lentivirus Available. Codon-optimized for respective species expression. >95% sequence identity verified. |
| Resistance Variant Profiling (Q141K, R482G/T) | Mutant ORF clones available (Q141K, R482G/T). Theoretical MW calculated. For mechanistic inhibitor selectivity and polymorphism impact. |
| Substrate vs Inhibitor Differentiation | R482G/T Mutant Variants included for altered substrate specificity. Combine ATPase assay with substrate accumulation assays. |
| False Positives in Toxicity Screens | Validated siRNA for specificity checks in counter-screening assays. Triple-transporter panel (ABCG2/ABCB1/ABCC1) for selectivity index. |
Live ABCG2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ABCG2 (CD338) modulators is intensifying, with major players shifting focus from first-generation broad-spectrum ABC inhibitors to next-generation selective ABCG2 modulators and allosteric inhibitors. As first-generation small molecule efflux inhibitors reached clinical hurdles due to off-target effects (e.g., ABCB1 inhibition causing neurotoxicity), the next wave of R&D is targeting highly specific, localized modulation. The emergence of ABCG2 as a definitive marker for cancer stem cells (side population) has shifted interest toward oncology applications beyond MDR reversal, particularly in combination regimens with chemotherapy and targeted agents. ADC payloads such as topoisomerase I inhibitors face efflux-mediated resistance in the clinic, driving demand for ABCG2-resistant payload design and combination strategies. Future outlook indicates growth in selective inhibitors, bispecific modulators (ABCG2/ABCB1), and targeted biologics (mAb, ADC) for CD338+ cancer stem cells.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Novartis, Takeda, Academic Consortia | Solid Tumors, MDR Reversal, Chemo-refractory Cancers | Efflux Inhibition Assay (Need ABCG2 stable cell lines with native membrane topology and ATPase activity) |
| ADC Resistance Modulators / Payload Optimization | Daiichi Sankyo, Seagen, Gilead | Metastatic Breast Cancer, SCLC, ABCG2-overexpressing Tumors | Intracellular Payload Accumulation Assay (Need paired ABCG2 WT vs Null isogenic lines and siRNA for specificity) |
| Blocking Antibodies | Early Biotech (Undisclosed) | Hematologic Malignancies, CD338+ Cancer Stem Cells | Surface Expression Verification (Need Lentivirus-based stable lines with conformational benchmark antibody 5D3) |
| Stem Cell Targeting / Diagnostics | Stemcell Technologies, Miltenyi, Stemline Therapeutics | Cancer Stem Cell Eradication, HSC Isolation | Side Population Assay (Hoechst 33342 efflux; Need functional expression systems and FACS controls) |
Related Targets & Cross-Sell Strategy
- ABCB1 (MDR1/P-gp): Synergistic efflux transporter; essential for selectivity index determination and comprehensive MDR studies.
- ABCC1 (MRP1): Compensatory resistance pathway; critical for off-target screening and ADME evaluation.
- TOP1 (Topoisomerase I): Direct target of ABCG2 substrate drugs (SN-38, topotecan); useful for combination rationale and ADC payload optimization.
- ALDH1A1: Co-marker with ABCG2 for cancer stem cells (side population); recommended for CSC research combos.
- CD47: Another CSC marker co-expressed with ABCG2 in leukemia stem cells; relevant for hematologic malignancy studies.